Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
China · Delayed Price · Currency is CNY 29.95
-1.34 (-4.28%)
Nov 13, 2026, 3:04 PM CST
SHE:300584 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 809.35 | 665.6 | 502.11 | 515.98 | 522.73 | 570.8 |
Other Revenue | 5.45 | 5.45 | 2.25 | 1.85 | 3.73 | 7.52 |
| 814.8 | 671.05 | 504.36 | 517.83 | 526.47 | 578.32 | |
Revenue Growth | 32.41% | 33.05% | -2.60% | -1.64% | -8.97% | -18.12% |
Cost of Revenue | 237.75 | 124.19 | 93.07 | 101.28 | 133.79 | 109.93 |
Gross Profit | 577.05 | 546.86 | 411.29 | 416.56 | 392.68 | 468.39 |
Selling, General & Admin | 392.27 | 409.4 | 309.65 | 313.51 | 325.99 | 403.48 |
Research & Development | 25.17 | 40.46 | 40.28 | 46.63 | 18.22 | 21.7 |
Other Operating Expenses | 14.54 | 14.57 | 9.8 | 8.81 | 9.77 | 12.48 |
Operating Expenses | 438.47 | 464.8 | 358.89 | 370.61 | 358.05 | 438.98 |
Operating Income | 138.58 | 82.06 | 52.4 | 45.94 | 34.63 | 29.41 |
Interest Expense | -5.9 | -6.66 | -8.98 | -8.27 | -7.25 | -7.5 |
Interest & Investment Income | 0.03 | 0.06 | 0.12 | 0.96 | 1.02 | 0.78 |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | -0.01 | 0.02 | 0.01 | -0.06 |
Other Non Operating Income (Expenses) | -7.97 | -0.04 | -0.23 | -0.09 | -0.54 | -0.02 |
EBT Excluding Unusual Items | 124.76 | 75.43 | 43.3 | 38.56 | 27.86 | 22.61 |
Gain (Loss) on Sale of Investments | -25.7 | -26.29 | - | 0.04 | 0.93 | 306.31 |
Gain (Loss) on Sale of Assets | -0.26 | 0.48 | - | -0.79 | -0.95 | -0.02 |
Asset Writedown | 3.7 | -4.4 | -2.09 | -0.04 | -0.92 | -0.29 |
Other Unusual Items | 2.08 | 2.08 | -0.19 | -0.08 | 1.86 | 1.83 |
Pretax Income | 104.57 | 47.3 | 41.03 | 37.69 | 28.78 | 330.45 |
Income Tax Expense | 28.12 | 6.57 | 0.87 | 1.37 | -3.35 | 45.61 |
Earnings From Continuing Operations | 76.45 | 40.73 | 40.16 | 36.32 | 32.12 | 284.83 |
Minority Interest in Earnings | -4.82 | 1.33 | 0.05 | - | 0.32 | 1.05 |
Net Income | 71.64 | 42.06 | 40.22 | 36.32 | 32.45 | 285.88 |
Net Income to Common | 71.64 | 42.06 | 40.22 | 36.32 | 32.45 | 285.88 |
Net Income Growth | 59.97% | 4.58% | 10.75% | 11.92% | -88.65% | 417.61% |
Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 | 120 |
Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 | 120 |
Shares Change | -0.03% | -0.02% | 0.01% | 0.01% | 0.00% | 0.01% |
EPS (Basic) | 0.60 | 0.35 | 0.34 | 0.30 | 0.27 | 2.38 |
EPS (Diluted) | 0.60 | 0.35 | 0.34 | 0.30 | 0.27 | 2.38 |
EPS Growth | 60.02% | 4.60% | 10.74% | 11.91% | -88.65% | 417.55% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 5.44 | 15.45 | -17.98 | -173.29 | -224.76 | -34.47 |
Free Cash Flow Per Share | 0.04 | 0.13 | -0.15 | -1.44 | -1.87 | -0.29 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.050 | - | 0.250 |
Dividend Growth | 0% | 0% | 100.00% | - | - | 100.00% |
Gross Margin | 70.82% | 81.49% | 81.55% | 80.44% | 74.59% | 80.99% |
Operating Margin | 17.01% | 12.23% | 10.39% | 8.87% | 6.58% | 5.09% |
Profit Margin | 8.79% | 6.27% | 7.97% | 7.01% | 6.16% | 49.43% |
Free Cash Flow Margin | 0.67% | 2.30% | -3.56% | -33.46% | -42.69% | -5.96% |
EBITDA | 210.72 | 145.96 | 105.33 | 99.49 | 82.69 | 66.41 |
EBITDA Margin | 25.86% | 21.75% | 20.88% | 19.21% | 15.71% | 11.48% |
D&A For EBITDA | 72.13 | 63.9 | 52.93 | 53.55 | 48.07 | 37 |
EBIT | 138.58 | 82.06 | 52.4 | 45.94 | 34.63 | 29.41 |
EBIT Margin | 17.01% | 12.23% | 10.39% | 8.87% | 6.58% | 5.09% |
Effective Tax Rate | 26.89% | 13.89% | 2.11% | 3.65% | - | 13.80% |
Revenue as Reported | 814.8 | 671.05 | 504.36 | 517.83 | 526.47 | 578.32 |